DiaMedica Therapeutics (DMAC) Total Current Liabilities (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Total Current Liabilities for 10 consecutive years, with $6.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 60.2% year-over-year to $6.6 million; the trailing twelve-month figure through Jun 2026 stood at $6.6 million (up 60.2% YoY), and the FY2025 full-year result was $5.1 million, down 4.79% from the prior year.
• Total Current Liabilities improved to $6.6 million in Q2 2026 per DMAC's latest filing, from $5.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $6.6 million in Q2 2026 and bottomed at $1.4 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $3.5 million across 5 years, with a median of $3.0 million in 2023.
• The widest YoY moves for Total Current Liabilities: up 98.02% in 2024, down 7.0% in 2024.
• Over 5 years, Total Current Liabilities stood at $2.2 million in 2022, then rose by 28.51% to $2.8 million in 2023, then surged by 93.47% to $5.4 million in 2024, then retreated by 4.79% to $5.1 million in 2025, then advanced by 28.49% to $6.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $6.6 million, $5.7 million, and $5.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.